Valuation: Immatics N.V.

Market Cap 1.18B 1.03B 970M 887M 1.66B 113B 1.67B 11.65B 4.52B 57.41B 4.41B 4.32B 186B P/E 2026 *
-4.07x
P/E 2027 * -4.09x
Enterprise Value 889M 781M 734M 671M 1.25B 85.19B 1.26B 8.81B 3.42B 43.43B 3.34B 3.27B 141B EV / Sales 2026 *
19.1x
EV / Sales 2027 * 21.1x
Free-Float
76.83%
Yield 2026 *
-
Yield 2027 * -
1 week-0.35%
Current month-9.76%
1 month-3.70%
3 months-13.18%
6 months-9.76%
Current year-18.02%
1 week 8.5
Extreme 8.5
9.02
1 month 8.37
Extreme 8.37
9.87
3 years 3.34
Extreme 3.34
13.75
5 years 3.34
Extreme 3.34
14.89
Manager TitleAgeSince
Chief Executive Officer 51 2018-12-31
Director of Finance/CFO 57 2025-09-30
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 51 2020-06-30
Chairman 70 2012-09-30
Director/Board Member 72 2020-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-2.99%-0.35%+20.79%-26.50% 1.18B
+0.06%+6.49%+60.29%+111.13% 74.18B
0.00%-3.69%+34.41%+75.19% 59.55B
-2.05%-3.46%-18.60%+352.20% 25.84B
-2.39%+2.74%+0.19%-5.91% 24.73B
-0.79%+1.29%+21.71%-9.84% 20.87B
+1.29%-2.49%+152.11%+333.06% 15.32B
-2.44%-0.09%+42.50%+164.11% 14.06B
-3.91%-4.91%-14.10%+779.68% 13.12B
-1.12%-3.04%+15.72%+234.56% 11.85B
Average -1.10%-0.40%+31.50%+200.77% 28.84B
Weighted average by Cap. -0.64%+0.70%+36.25%+160.57%

Financials

2026 *2027 *
Net sales 46.54M 40.85M 38.4M 35.1M 65.6M 4.46B 66.08M 461M 179M 2.27B 175M 171M 7.37B 39.58M 34.74M 32.66M 29.86M 55.79M 3.79B 56.21M 392M 152M 1.93B 149M 145M 6.27B
Net income -287M -252M -237M -217M -405M -27.53B -408M -2.85B -1.1B -14.04B -1.08B -1.06B -45.51B -310M -272M -255M -234M -436M -29.66B -440M -3.07B -1.19B -15.12B -1.16B -1.14B -49.03B
Net Debt -286M -251M -236M -216M -403M -27.41B -406M -2.84B -1.1B -13.98B -1.07B -1.05B -45.32B -339M -297M -279M -255M -477M -32.44B -481M -3.36B -1.3B -16.54B -1.27B -1.24B -53.63B
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
-
Date Price Change
26-09-23 US$8.600 -2.99%
26-09-22 US$8.865 +1.66%
26-09-21 US$8.720 +1.40%
26-09-18 US$8.600 -2.49%
26-09-17 US$8.820 +2.20%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
8.600USD
Average target price
17.63USD
Spread / Average Target
+105.04%

Quarterly revenue - Rate of surprise